The receptor used by baculovirus to enter and interact with human cells has been identified. This syndecan–1 receptor was identified for the first time in a recent collaborative study carried out by the University of Eastern ...
Sep 27, 2013
0
0
While cancer survivors require follow-up care to prevent a recurrence of their cancer and to watch for after effects of treatment, they also need the same preventive check-ups suggested for all people.
Aug 7, 2013
0
0
"Borreliosis" or "Lyme disease" is caused by the bacterium "Borrelia burgdorferi". In Austria approximately 16,000 people fall ill with borreliosis annually following a tick bite. Roughly every fifth tick in Austria carries ...
May 14, 2013
0
0
Over 40,000 people die each year in the United States from influenza-related diseases. In patients whose immune systems are compromised, antiviral therapy may be life-saving, but it needs to be initiated quickly. It is therefore ...
Apr 17, 2013
0
0
As part of a multicenter clinical trial, researchers at University of California, San Diego School of Medicine are evaluating Pexa-Vec (JX-594) to slow the progression of hepatocellular carcinoma (HCC) or liver cancer. Pexa-Vec ...
Apr 10, 2013
0
0
Multi-peptide vaccination therapy combined with the low-dose steroid drug dexamethasone shows promise in treating chemotherapy-naive castration resistant prostate cancer (CRPC) patients.
Mar 15, 2013
0
0
Preclinical, laboratory studies suggest a novel immunotherapy could potentially work like a vaccine against metastatic cancers, according to scientists at Virginia Commonwealth University Massey Cancer Center. Results from ...
Feb 27, 2013
0
0
A team of Spanish researchers say they have developed a therapeutic vaccine that can temporarily brake growth of the HIV virus in infected patients.
Jan 3, 2013
3
0
Early results of a trial to treat leukaemia with a WT1 DNA vaccine, has shown robust vaccine-specific antibody responses in all vaccinated patients evaluated to date.
Dec 7, 2012
0
0
Select patients with advanced prostate cancer may benefit from a Georgia Health Sciences University Cancer Center clinical trial that looks to improve survival rates of the FDA-approved prostate cancer drug Provenge.
Dec 3, 2012
0
1
